Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543.
CTP-543 is a Novel JAK Inhibitor in Phase 2 for Alopecia Areata as Potential First-in-Class Treatment LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company's Post Grant Review (PGR) petition challenging the validity of U.S. Patent No.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018 . Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017 .
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. "This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our
CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial
LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017 , at 11:10 a.m. EDT at the Westin Waterfront in Boston .
